Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345
Sydnexis Signs $23M Agreement With Ligand Pharmaceuticals To Sell Its Royalty Rights Associated With Net Sales Of Ryjunea In EMEA